A 2016 study showed that MALT1 (mucosa-associated lymphoid tissue 1) is involved in EGFR-induced NF-κB activation in lung cancer cells, and that MALT1 inhibition impaired EGFR-dependent NF-κB activation [107]. This evidence concerns the gene EGFR and lung cancer.